James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.
James M. Rossetti, DO
Advertisement
Articles by James M. Rossetti, DO
James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.
James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.
James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.
James M. Rossetti, DO, hematologist, UPMC Hillman Cancer Center, discusses risk stratification in myeloproliferative neoplasms (MPNs).
Advertisement
Latest Updated Articles
Dr. Rossetti on Symptom Management for Patients With MPNsFebruary 21st 2020
Dr. Rossetti on Symptom Management for MPNsFebruary 27th 2020
Dr. Rossetti on the Utility of JAK Inhibitors in MPNsApril 21st 2020
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
The OncFive: Top Oncology Articles for the Week of 7/12
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5